

Certificate of Approval of a Prospectus
pursuant to Prospectus Regulation (EU) 2017/1129 of the European Parliament and of the Council

To: Autorité des Marchés Financiers, France

From: Financial Services and Markets Authority (FSMA), Belgium

We hereby certify that the Prospectus detailed below has been drawn up pursuant to Prospectus Regulation (EU) 2017/1129 of the European Parliament and of the Council and was approved by us on 8 June 2021.

Name of Issuer(s): Celyad Oncology

LEI: 549300ORR0M8XF56OI64

Registered Office(s): Rue Edouard Belin 2, 1435 MONT-SAINT-GUIBERT

Type of Securities (if applicable): Shares

National Prospectus Identifier: SECNOTE-2021-003326

references to the annexes of Regulation (EU) 2019/980 used: III and XII

Signed:



Recoverable Signature

X Jean-Paul Servais

Jean-Paul SERVAIS

Président

Signed by: Jean-Paul Servais (Signature)

For and on behalf of the: Financial Services and Markets Authority (FSMA)

Date: 8 juin 2021

Attachments: (1) Prospectus
(2) Translation Summary (French)